2025, Number 3
<< Back Next >>
Aten Fam 2025; 32 (3)
Evaluation and Acceptance of Microneedle Patches (MAP) as a New Form of Vaccination
Romero-Aguilar S, Sánchez-Saldaña A
Language: Spanish
References: 6
Page: 223-225
PDF size: 168.60 Kb.
Text Extraction
No abstract.
REFERENCES
Berger MN, Davies C, Mathieu E, Shaban RZ,Bag S, Skinner SR. Developing and validating ascale to measure the perceptions of safety, usabilityand acceptability of microarray patches for vaccination:a study protocol. Ther Adv Vaccines Immunother. 2024;12:25151355241263560.
Soble A, Ko M, Gilchrist S, Malvolti S, Hasso-Agopsowicz M, Giersing B, et al. A review ofpotential use cases for measles-rubella, measlesmumps-rubella, and typhoid-conjugate vaccinespresented on microarray patches. Vaccine. 2024;42(6):1230-1246.
Hasso-Agopsowicz M, Spasenoska D, JansenMPM, Masresha BG, Pastor D, Gebrekidan AH,et al. Exploring Important Attributes, the PotentialUse Cases and Feasibility of Introduction of Measlesand Rubella Microarray Patches (MR-MAPs):Insights from Nine Countries. Vaccines (Basel).2024;12(9):1084.
Masoud D, Pierz A, Rauh L, Cruz AK, PalmedoC, Ratzan S. Vaccine Trust Gauge: Mixed methodsresearch to measure and understand vaccine trust.Vaccine. 2023;41(31):4616-4624.
Malas O, Tolsá MD. Needle-related Fear versusVaccination Fear, Vaccination Intention, and DeclaredReasons for Avoiding Vaccination. Clin Salud.2022;33(3):101-107.
Ko M, Frivold C, Mvundura M, Soble A, GregoryC, Christiansen H, et al. An Application of anInitial Full Value of Vaccine Assessment Methodologyto Measles-Rubella MAPs for Use in LowandMiddle-Income Countries. Vaccines (Basel).2024;12(9):1075.
Full text